Skip to main content

Advertisement

Table 2 Clinical effects of monotherapeutic PD-1 signal inhibitors on several types of malignancies

From: Cancer immunotherapies targeting the PD-1 signaling pathway

Target Agent Phase Clinical effect Reference
melanoma pembrolizumab 2 6MOS 34% (2 mg/kg) vs. 38% (10 mg/kg), vs 16% :docetaxel (n = 540) [88]
3 1 year-OS 74% (2wks) vs. 38% (3wks), vs 11% :docetaxel (n = 834) [89]
nivolumab 3 1 year-OS 73% vs 42% (dacarbazine) (n = 418) [89]
3 ORR 32% vs. 11% (dacarbazine) (n = 405) [90]
non-small cell lung cancer pembrolizumab 1 ORR 19.4%, mOS12.5 M (total), ORR 45.2% (n = 72, PD-L1+) (n = 495) [91]
nivolumab 3 mOS 9.2 M (vs 6.0 M:docetaxel) (n = 272) [57]
3 mOS12.2 M (vs 9.7 M:docetaxel (n = 582) [92]
durvalumab 1/2 ORR 14% (n = 149, total), 23% (PD-L1+) [72]
atezolizumab 2 ORR 15% (n = 144, total), 38% (n = 24, PD-L1+) [93]
small cell lung cancer nivolumab 1/2 ORR 18% (n = 40, nivo), 17% (n = 46, combined with chemotherapy) [94]
pembrolizumab 1 ORR 25% (n = 16) [95]
head and neck cancer durvalumab 1/2 ORR 12% (n = 62) [96]
pembrolizumab 1 ORR 24.8% (n = 117) [97]
renal cell cancer nivolumab 3 ORR 25%, mOS 25.0 M, (vs. ORR 5%, mOS 19Ms in everolimus) (n = 821) [98]
bladder cancer atezolizumab 1 ORR 26% (n = 310, total), 43% (PD-L1+) [99]
pembrolizumab 1 ORR 25% (n = 33, total), 38% (PD-L1+) [100]
ovarian cancer nivolumab 2 ORR 15% (n = 20, total), mOS 20.0 M ORR 20% (n = 10, 3 mg/kg) [60]
avelumab 1 ORR 10% (n = 124) [101]
pembrolizumab 1 ORR 11.5% (PD-L1+) (n = 49) [63]
uterine endometrial cancer pembrolizumab 1 ORR 12.5% (PD-L1+) (n = 24) [102]
uterine cervical cancer pembrolizumab 1 ORR 12.5% (PD-L1+) (n = 24) [103]
uterine sarcoma nivolumab 1 ORR 0% (n = 12) [104]
gastric cancer pembrolizumab 1 ORR 31% (n = 39) [79]
esophageal cancer pembrolizumab 1 ORR 30% (PD-L1+) (n = 23) [105]
DNA mismatch repair deficient colon pembrolizumab 2 ORR 40% (n = 10, MMRd colon), vs 0% (n = 18) in MMRw, vs71% (n = 7), MMR-non-colon [cholangiocarcinoma, endometrial cancer and pancreatic cancer].) [73].
DNA mismatch repair deficient endometrial cancer pembrolizumab 2 ir-ORR 67% (n = 9) [106]
hepatocellular carcinoma nivolumab 1/2 ORR 9% (n = 91), 6 month-OS 69%. [107]
breast cancer atezolizumab 1 ORR 12% (n = 27) [108]
pembrolizumab 1 ORR 19% (n = 25) (PD-L1+) [109]
Merkel cell carcinoma pembrolizumab 2 ORR 56% (n = 25), 6 M-PFS 67% [110]
thyroid cancer pembrolizumab 1 ORR 9.1% (n = 22), mOS not reached, 1 year-OS 89.9%. [111]
Hodgikin lymphoma nivolumab 1 ORR 87%, 24wks-PFS 86%(n = 23) [112]
pembrolizumab 1 ORR 64% (n = 31), 52wks-PFS 46%. [113]
follicular lymphoma nivolumab 1 ORR 40% (n = 10) [114]
diffuse large B-cell lymphoma nivolumab 1 ORR 36% (n = 11) [114]
mycosisfungoides nivolumab 1 ORR 15% (n = 13) [114]
peripheral T-cell lymphoma nivolumab 1 ORR 40% (n = 5) [114]
  1. Partially modified from reference [58]. Abbreviations: M month, wk week, ORR objective response rate, OS overall survival, PFS progression-free survival, irRC immune-related response criteria, ASCO Annual meeting of the American Society of Clinical Oncology, SGO Annual meeting of the Society of Gynecologic Oncology, Abst Abstract, MMRd DNA mismatch repair deficient, MMRw DNA mismatch repair wild